1. Generics Bulletin
  2. >>Legal & IP

MPP And WHO Announce COVID Technology License Via C-TAP

Serological Antibody Technology Deal Struck With Spanish National Research Council

 
• By Dave Wallace

The WHO and Medicines Patent Pool have announced “the first transparent, global, non-exclusive license for a COVID-19 technology” after striking a deal for a COVID-19 serological antibody technology with the Spanish National Research Council through the WHO’s COVID-19 Technology Access Pool.

WHO
The WHO and MPP have announced a COVID-19 technology licensing deal • Source: Alamy

The World Health Organization and Medicines Patent Pool have announced “the first transparent, global, non-exclusive license for a COVID-19 technology,” in the form of a deal for a COVID-19 serological antibody technology with the Spanish National Research Council.

Secured via the WHO’s COVID-19 Technology Access Pool – launched in mid-2020 (Also see "WHO Launches COVID-19 Technology Access Pool" - Generics Bulletin, 2 June, 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.